Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer

Oral Oncology

Volumn 58, Issue , 2016, Pages 59-70

  Davis, Ruth J ^a   Van Waes, Carter ^a   Allen, Clint T ^a,b  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigenicity; Immunity; Immunogenicity; Immunotherapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BASILIXIMAB; BLOCKING ANTIBODY; CCR4 MONOCLONAL ANTIBODY; CD134 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; COLECALCIFEROL; CTLA4 MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GITR MONOCLONAL ANTIBODY; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HYDROLASE INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; MONOCLONAL ANTIBODY; N(G) METHYLARGININE; NOR NOHA; OX40 MONOCLONAL ANTIBODY; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR BLOCKING ANTIBODY; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CELL POLARITY; DRUG TARGETING; HEAD AND NECK CANCER; HOST CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; HEAD AND NECK TUMOR; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; MYELOID-DERIVED SUPPRESSOR CELL;

HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MACROPHAGES; MYELOID-DERIVED SUPPRESSOR CELLS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84969524562     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2016.05.002     Document Type: Article

References (130)

1. [1] Cancer Genome Atlas Network, Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517 (2015), 576–582, 10.1038/nature14129.
2. [2] Ott, P.A., Adams, S., Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy 3 (2011), 213–227, 10.2217/imt.10.99.
3. [3] Shimizu, T., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., Smith, L.S., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18 (2012), 2316–2325, 10.1158/1078-0432.CCR-11-2381.
4. [4] Sok, J.C., Coppelli, F.M., Thomas, S.M., Lango, M.N., Xi, S., Hunt, J.L., et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12 (2006), 5064–5073, 10.1158/1078-0432.CCR-06-0913.
5. [5] Champiat, S., Ferte, C., Lebel-Binay, S., Eggermont, A., Soria, J.C., Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology, 3, 2014, e27817, 10.4161/onci.27817.
6. [6] Keck, M.K., Zuo, Z., Khattri, A., Stricker, T.P., Brown, C.D., Imanguli, M., et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res 21 (2015), 870–881, 10.1158/1078-0432.CCR-14-2481.
7. [7] Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218, 10.1038/nature12213.
8. [8] Wolf, G.T., Chepeha, D.B., Bellile, E., Nguyen, A., Thomas, D., McHugh, J., Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol 51 (2015), 90–95, 10.1016/j.oraloncology.2014.09.006.
9. [9] Seiwert, T.Y., Haddad, R.I., Gupta, S., Mehra, R., Tahara, M., Berger, R., et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J Clin Oncol, 33, 2015.
10. [10] Allen, C.T., Clavijo, P.E., Van Waes, C., Chen, Z., Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches. Cancers (Basel) 7 (2015), 2397–2414, 10.3390/cancers7040900.
11. [11] Mandruzzato, S., Brasseur, F., Andry, G., Boon, T., van der Bruggen, P., A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 186 (1997), 785–793.
12. [12] Yu, P., Lee, Y., Liu, W., Chin, R.K., Wang, J., Wang, Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5 (2004), 141–149, 10.1038/ni1029.
13. [13] Smyth, M.J., Crowe, N.Y., Godfrey, D.I., NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13 (2001), 459–463.
14. [14] Schantz, S.P., Shillitoe, E.J., Brown, B., Campbell, B., Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst 77 (1986), 869–875.
15. [15] Balermpas, P., Michel, Y., Wagenblast, J., Seitz, O., Weiss, C., Rodel, F., et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 110 (2014), 501–509, 10.1038/bjc.2013.640.
16. [16] Allen, C.T., Judd, N.P., Bui, J.D., Uppaluri, R., The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope 122 (2012), 144–157, 10.1002/lary.21913.
17. [17] Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 (2012), 883–892, 10.1056/NEJMoa1113205.
18. [18] D'Amico, L., Mahajan, S., Capietto, A.-H., Yang, Z., Zamani, A., Ricci, B., et al. Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. J Exp Med, 2016, 10.1084/jem.20150950.
19. [19] Ariffin, A.B., Forde, P.F., Jahangeer, S., Soden, D.M., Hinchion, J., Releasing pressure in tumors: what do we know so far and where do we go from here? A review. Cancer Res 74 (2014), 2655–2662, 10.1158/0008-5472.CAN-13-3696.
20. [20] Le, Q.T., Shi, G., Cao, H., Nelson, D.W., Wang, Y., Chen, E.Y., et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23 (2005), 8932–8941, 10.1200/JCO.2005.02.0206.
21. [21] van Baren, N., Van den Eynde, B.J., Tumoral immune resistance mediated by enzymes that degrade tryptophan. Cancer Immunol Res, 2015, 1–9, 10.1158/2326-6066.CIR-15-0095.
22. [22] Lathers, D.M., Young, M.R., Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine 25 (2004), 220–228, 10.1016/j.cyto.2003.11.005.
23. [23] Lu, S.L., Reh, D., Li, A.G., Woods, J., Corless, C.L., Kulesz-Martin, M., et al. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 64 (2004), 4405–4410, 10.1158/0008-5472.CAN-04-1032.
24. [24] Chang, C.H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241, 10.1016/j.cell.2015.08.016.
25. [25] Ho, P.C., Bihuniak, J.D., Macintyre, A.N., Staron, M., Liu, X., Amezquita, R., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162 (2015), 1217–1228, 10.1016/j.cell.2015.08.012.
26. [26] Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Parmentier, N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003), 1269–1274, 10.1038/nm934.
27. [27] Zou, W., Chen, L., Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8 (2008), 467–477, 10.1038/nri2326.
28. [28] Topalian, S.L., Drake, C.G., Pardoll, D.M., Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24 (2012), 207–212, 10.1016/j.coi.2011.12.009.
29. [29] Chen, J., Feng, Y., Lu, L., Wang, H., Dai, L., Li, Y., et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 217 (2012), 385–393, 10.1016/j.imbio.2011.10.016.
30. [30] Thomas, G.R., Chen, Z., Leukinova, E., Van Waes, C., Wen, J., Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma. Cancer Immunol Immunother 53 (2004), 33–40, 10.1007/s00262-003-0433-4.
31. [31] Gajewski, T.F., Schreiber, H., Fu, Y.X., Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14 (2013), 1014–1022, 10.1038/ni.2703.
32. [32] Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9 (2009), 162–174, 10.1038/nri2506.
33. [33] Pak, A.S., Wright, M.A., Matthews, J.P., Collins, S.L., Petruzzelli, G.J., Young, M.R., Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1 (1995), 95–103.
34. [34] Loukinova, E., Dong, G., Enamorado-Ayalya, I., Thomas, G.R., Chen, Z., Schreiber, H., et al. Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19 (2000), 3477–3486, 10.1038/sj.onc.1203687.
35. [35] Smith, C.W., Chen, Z., Dong, G., Loukinova, E., Pegram, M.Y., Nicholas-Figueroa, L., et al. The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Clin Exp Metastasis 16 (1998), 655–664.
36. [36] Almand, B., Clark, J.I., Nikitina, E., van Beynen, J., English, N.R., Knight, S.C., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166 (2001), 678–689.
37. [37] Weed, D.T., Vella, J.L., Reis, I.M., De la Fuente, A.C., Gomez, C., Sargi, Z., et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21 (2015), 39–48, 10.1158/1078-0432.CCR-14-1711.
38. [38] Highfill, S.L., Cui, Y., Giles, A.J., Smith, J.P., Zhang, H., Morse, E., et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med, 6, 2014, 237ra67, 10.1126/scitranslmed.300797.
39. [39] Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203 (2006), 2691–2702, 10.1084/jem.20061104.
40. [40] Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S.K., Dubois, R.N., CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24 (2013), 631–644, 10.1016/j.ccr.2013.10.009.
41. [41] Lesokhin, A.M., Hohl, T.M., Kitano, S., Cortez, C., Hirschhorn-Cymerman, D., Avogadri, F., et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 72 (2012), 876–886, 10.1158/0008-5472.CAN-11-1792.
42. [42] Zhu, Y., Knolhoff, B.L., Meyer, M.A., Nywening, T.M., West, B.L., Luo, J., et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74 (2014), 5057–5069, 10.1158/0008-5472.CAN-13-3723.
43. [43] Chen, Z., Malhotra, P.S., Thomas, G.R., Ondrey, F.G., Duffey, D.C., Smith, C.W., et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5 (1999), 1369–1379.
44. [44] Keane, M.P., Belperio, J.A., Xue, Y.Y., Burdick, M.D., Strieter, R.M., Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 172 (2004), 2853–2860.
45. [45] Draghiciu, O., Lubbers, J., Nijman, H.W., Daemen, T., Myeloid derived suppressor cells – an overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology, 4, 2015, e954829, 10.4161/21624011.2014.954829.
46. [46] Lechner, M.G., Liebertz, D.J., Epstein, A.L., Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185 (2010), 2273–2284, 10.4049/jimmunol.1000901.
47. [47] Dong, G., Chen, Z., Kato, T., Van Waes, C., The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 59 (1999), 3495–3504.
48. [48] Rodriguez, P.C., Hernandez, C.P., Quiceno, D., Dubinett, S.M., Zabaleta, J., Ochoa, J.B., et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202 (2005), 931–939, 10.1084/jem.20050715.
49. [49] Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190 (2013), 3783–3797, 10.4049/jimmunol.1201449.
50. [50] Srivastava, M.K., Sinha, P., Clements, V.K., Rodriguez, P., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70 (2010), 68–77, 10.1158/0008-5472.CAN-09-2587.
51. [51] Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 123 (2013), 1580–1589, 10.1172/JCI60083.
52. [52] Noman, M.Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211 (2014), 781–790, 10.1084/jem.20131916.
53. [53] Chikamatsu, K., Sakakura, K., Toyoda, M., Takahashi, K., Yamamoto, T., Masuyama, K., Immunosuppressive activity of CD14+ HLA-DR-cells in squamous cell carcinoma of the head and neck. Cancer Sci 103 (2012), 976–983, 10.1111/j.1349-7006.2012.02248.x.
54. [54] Nagaraj, S., Schrum, A.G., Cho, H.-I., Celis, E., Gabrilovich, D.I., Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 184 (2010), 3106–3116, 10.4049/jimmunol.0902661.
55. [55] Nishikawa, H., Sakaguchi, S., Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 27 (2014), 1–7, 10.1016/j.coi.2013.12.005.
56. [56] Huang, B., Pan, P.Y., Li, Q., Sato, A.I., Levy, D.E., Bromberg, J., et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66 (2006), 1123–1131, 10.1158/0008-5472.CAN-05-1299.
57. [57] Hoechst, B., Ormandy, L.A., Ballmaier, M., Lehner, F., Kruger, C., Manns, M.P., et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135 (2008), 234–243, 10.1053/j.gastro.2008.03.020.
58. [58] Serafini, P., Mgebroff, S., Noonan, K., Borrello, I., Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68 (2008), 5439–5449, 10.1158/0008-5472.CAN-07-6621.
59. [59] Pan, P.Y., Ma, G., Weber, K.J., Ozao-Choy, J., Wang, G., Yin, B., et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70 (2010), 99–108, 10.1158/0008-5472.CAN-09-1882.
60. [60] Garrity, T., Pandit, R., Wright, M.A., Benefield, J., Keni, S., Young, M.R., Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer 73 (1997), 663–669.
61. [61] Lathers, D.M., Clark, J.I., Achille, N.J., Young, M.R., Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother 53 (2004), 422–430, 10.1007/s00262-003-0459-7.
62. [62] Walsh, J.E., Clark, A.M., Day, T.A., Gillespie, M.B., Young, M.R., Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol 71 (2010), 659–665, 10.1016/j.humimm.2010.04.008.
63. [63] Serafini, P., Borrello, I., Bronte, V., Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16 (2006), 53–65, 10.1016/j.semcancer.2005.07.005.
64. [64] Okusaka, T., Ueno, H., Ikeda, M., Mitsunaga, S., Ozaka, M., Ishii, H., et al. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res, 2015, 10.1111/hepr.12504.
65. [65] Hong, D.S., Younes, A., Fayad, L., Fowler, N.H., Hagemeister, F.B., Mistry, R., et al. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J Clin Oncol, 31, 2013 suppl; abstr 8523.
66. [66] Seung, L.P., Rowley, D.A., Dubey, P., Schreiber, H., Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 92 (1995), 6254–6258.
67. [67] Srivastava, M.K., Zhu, L., Harris-White, M., Kar, U.K., Huang, M., Johnson, M.F., et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE, 7, 2012, e40677, 10.1371/journal.pone.0040677.
68. [68] Stadtmann, A., Zarbock, A., CXCR2: from bench to bedside. Front Immunol, 3, 2012, 263, 10.3389/fimmu.2012.00263.
69. [69] Califano, J.A., Khan, Z., Noonan, K.A., Rudraraju, L., Zhang, Z., Wang, H., et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 21 (2015), 30–38, 10.1158/1078-0432.CCR-14-1716.
70. [70] O'Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C.M., Arthur, C., White, J.M., et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 209 (2012), 1869–1882, 10.1084/jem.20112738.
71. [71] Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van Bossche, J., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 70 (2010), 5728–5739, 10.1158/0008-5472.CAN-09-4672.
72. [72] Costa, N.L., Valadares, M.C., Souza, P.P., Mendonca, E.F., Oliveira, J.C., Silva, T.A., et al. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol 49 (2013), 216–223, 10.1016/j.oraloncology.2012.09.012.
73. [73] Marcus, B., Arenberg, D., Lee, J., Kleer, C., Chepeha, D.B., Schmalbach, C.E., et al. Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer 101 (2004), 2779–2787, 10.1002/cncr.20701.
74. [74] Galdiero, M.R., Bonavita, E., Barajon, I., Garlanda, C., Mantovani, A., Jaillon, S., Tumor associated macrophages and neutrophils in cancer. Immunobiology 218 (2013), 1402–1410, 10.1016/j.imbio.2013.06.003.
75. [75] Chanmee, T., Ontong, P., Konno, K., Itano, N., Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 6 (2014), 1670–1690, 10.3390/cancers6031670.
76. [76] Shah, S., Cash, H., Van Waes, C., Allen, C., Pools of programmed death ligand within the oral cavity tumor microenvironment are variable altered by targeted therapies. Head Neck, 2015.
77. [77] Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61, 10.1016/j.immuni.2014.06.010.
78. [78] Marchesi, M., Andersson, E., Villabona, L., Seliger, B., Lundqvist, A., Kiessling, R., et al. HLA-dependent tumour development: a role for tumour associate macrophages?. J Transl Med, 11, 2013, 247, 10.1186/1479-5876-11-247.
79. [79] Murai, M., Turovskaya, O., Kim, G., Madan, R., Karp, C.L., Cheroutre, H., et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 10 (2009), 1178–1184, 10.1038/ni.1791.
80. [80] Chang, L.Y., Lin, Y.C., Mahalingam, J., Huang, C.T., Chen, T.W., Kang, C.W., et al. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8 + T cells in colon cancer by T-regulatory cells. Cancer Res 72 (2012), 1092–1102, 10.1158/0008-5472.CAN-11-2493.
81. [81] Chen, K.J., Lin, S.Z., Zhou, L., Xie, H.Y., Zhou, W.H., Taki-Eldin, A., et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One, 6, 2011, 10.1371/journal.pone.002467.
82. [82] Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004), 942–949, 10.1038/nm1093.
83. [83] Mok, S., Koya, R.C., Tsui, C., Xu, J., Robert, L., Wu, L., et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 74 (2014), 153–161, 10.1158/0008-5472.CAN-13-1816.
84. [84] DeNardo, D.G., Brennan, D.J., Rexhepaj, E., Ruffell, B., Shiao, S.L., Madden, S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1 (2011), 54–67, 10.1158/2159-8274.CD-10-0028.
85. [85] Ries, C.H., Cannarile, M.A., Hoves, S., Benz, J., Wartha, K., Runza, V., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25 (2014), 846–859, 10.1016/j.ccr.2014.05.016.
86. [86] Dineen, S.P., Lynn, K.D., Holloway, S.E., Miller, A.F., Sullivan, J.P., Shames, D.S., et al. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 68 (2008), 4340–4346, 10.1158/0008-5472.CAN-07-6705.
87. [87] Shime, H., Matsumoto, M., Oshiumi, H., Tanaka, S., Nakane, A., Iwakura, Y., et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci 109 (2012), 2066–2071, 10.1073/pnas.1113099109.
88. [88] Zhang, X., Tian, W., Cai, X., Wang, X., Dang, W., Tang, H., et al. Hydrazinocurcumin encapsuled nanoparticles “Re-Educate” tumor-associated macrophages and exhibit anti-tumor effects on breast cancer following STAT3 suppression. PLoS One, 8, 2013, 10.1371/journal.pone.006589.
89. [89] Coscia, M., Quaglino, E., Iezzi, M., Curcio, C., Pantaleoni, F., Riganti, C., et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14 (2010), 2803–2815, 10.1111/j.1582-4934.2009.00926.x.
90. [90] Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19 (2011), 31–44, 10.1016/j.ccr.2010.11.009.
91. [91] Downey, C.M., Aghaei, M., Schwendener, R.A., Jirik, F.R., DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2′3′-cGAMP, induces M2 macrophage repolarization. PLoS One, 9, 2014, 10.1371/journal.pone.009998.
92. [92] Baird, J.R., Friedman, D., Cottam, B., Dubensky, T.W., Kanne, D.B., Bambina, S., et al. Radiotherapy combined with Novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res 76 (2015), 50–61, 10.1158/0008-5472.CAN-14-3619.
93. [93] Weed, D.T., Walker, G., De La Fuente, A.C., Nazarian, R., Vella, J.L., Gomez-Fernandez, C.R., et al. FOXP3 subcellular localization predicts recurrence in oral squamous cell carcinoma. PLoS ONE, 8, 2013, e71908, 10.1371/journal.pone.0071908.
94. [94] Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay Nel, H., et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12 (2006), 465–472, 10.1158/1078-0432.CCR-05-1886.
95. [95] Strauss, L., Bergmann, C., Gooding, W., Johnson, J.T., Whiteside, T.L., The frequency and suppressor function of CD4 + CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13 (2007), 6301–6311, 10.1158/1078-0432.CCR-07-1403.
96. [96] Zhou, G., Levitsky, H.I., Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 178 (2007), 2155–2162, 10.4049/jimmunol.178.4.2155.
97. [97] Valzasina, B., Piconese, S., Guiducci, C., Colombo, M.P., Tumor-induced expansion of regulatory T cells by conversion of CD4 + CD25-lymphocytes is thymus and proliferation independent. Cancer Res 66 (2006), 4488–4495, 10.1158/0008-5472.CAN-05-4217.
98. [98] Jie, H.B., Gildener-Leapman, N., Li, J., Srivastava, R.M., Gibson, S.P., Whiteside, T.L., et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 109 (2013), 2629–2635, 10.1038/bjc.2013.645.
99. [99] Sugiyama, D., Nishikawa, H., Maeda, Y., Nishioka, M., Tanemura, A., Katayama, I., et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 110 (2013), 17945–17950, 10.1073/pnas.1316796110.
100. [100] Facciabene, A., Peng, X., Hagemann, I.S., Balint, K., Barchetti, A., Wang, L.P., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475 (2011), 226–230, 10.1038/nature10169.
101. [101] Redjimi, N., Raffin, C., Raimbaud, I., Pignon, P., Matsuzaki, J., Odunsi, K., et al. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res 72 (2012), 4351–4360, 10.1158/0008-5472.CAN-12-0579.
102. [102] Coombes, J.L., Siddiqui, K.R., Arancibia-Carcamo, C.V., Hall, J., Sun, C.M., Belkaid, Y., et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204 (2007), 1757–1764, 10.1084/jem.20070590.
103. [103] Sun, C.M., Hall, J.A., Blank, R.B., Bouladoux, N., Oukka, M., Mora, J.R., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 204 (2007), 1775–1785, 10.1084/jem.20070602.
104. [104] Perez, N., Karumuthil-Melethil, S., Li, R., Prabhakar, B.S., Holterman, M.J., Vasu, C., Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+)-adaptive regulatory T cell generation. J Immunol 180 (2008), 6566–6576.
105. [105] Pallandre, J.R., Brillard, E., Crehange, G., Radlovic, A., Remy-Martin, J.P., Saas, P., et al. Role of STAT3 in CD4 + CD25 + FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J Immunol 179 (2007), 7593–7604.
106. [106] Ahmadzadeh, M., Rosenberg, S.A., IL-2 administration increases CD4 + CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107 (2006), 2409–2414, 10.1182/blood-2005-06-2399.
107. [107] Bonertz, A., Weitz, J., Pietsch, D.H., Rahbari, N.N., Schlude, C., Ge, Y., et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 119 (2009), 3311–3321, 10.1172/JCI39608.
108. [108] Nishikawa, H., Kato, T., Tawara, I., Takemitsu, T., Saito, K., Wang, L., et al. Accelerated chemically induced tumor development mediated by CD4 + CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci USA 102 (2005), 9253–9257, 10.1073/pnas.0503852102.
109. [109] Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J.T., Whiteside, T.L., A unique subset of CD4 + CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13 (2007), 4345–4354, 10.1158/1078-0432.CCR-07-0472.
110. [110] Bergmann, C., Strauss, L., Wang, Y., Szczepanski, M.J., Lang, S., Johnson, J.T., et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14 (2008), 3706–3715, 10.1158/1078-0432.CCR-07-5126.
111. [111] Cao, X., Cai, S.F., Fehniger, T.A., Song, J., Collins, L.I., Piwnica-Worms, D.R., et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27 (2007), 635–646, 10.1016/j.immuni.2007.08.014.
112. [112] Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:80 (2008), 271–275, 10.1126/science.116006.
113. [113] Deaglio, S., Dwyer, K.M., Gao, W., Friedman, D., Usheva, A., Erat, A., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204 (2007), 1257–1265, 10.1084/jem.20062512.
114. [114] Jacobs, J.F., Punt, C.J., Lesterhuis, W.J., Sutmuller, R.P., Brouwer, H.M., Scharenborg, N.M., et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res 16 (2010), 5067–5078, 10.1158/1078-0432.CCR-10-1757.
115. [115] Rech, A.J., Mick, R., Martin, S., Recio, A., Aqui, N.A., Powell, D.J. Jr., et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med, 4, 2012, 134ra62, 10.1126/scitranslmed.300333.
116. [116] Whelan, M.C., Casey, G., Larkin, J.O., Guinn, B.A., O'Sullivan, G.C., Tangney, M., Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. PLoS ONE, 9, 2014, e97602, 10.1371/journal.pone.0097602.
117. [117] Kurose, K., Ohue, Y., Wada, H., Iida, S., Ishida, T., Kojima, T., et al. Phase Ia study of FoxP3 + CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res 21 (2015), 4327–4336, 10.1158/1078-0432.CCR-15-0357.
118. [118] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723, 10.1056/NEJMoa1003466.
119. [119] Selby, M.J., Engelhardt, J.J., Quigley, M., Henning, K.A., Chen, T., Srinivasan, M., et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1 (2013), 32–42, 10.1158/2326-6066.CIR-13-0013.
120. [120] Jie, H.B., Schuler, P.J., Lee, S.C., Srivastava, R.M., Argiris, A., Ferrone, S., et al. CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 75 (2015), 2200–2210, 10.1158/0008-5472.CAN-14-2788.
121. [121] Turk, M.J., Guevara-Patino, J.A., Rizzuto, G.A., Engelhorn, M.E., Sakaguchi, S., Houghton, A.N., Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200 (2004), 771–782, 10.1084/jem.20041130.
122. [122] Weinberg, A.D., Rivera, M.M., Prell, R., Morris, A., Ramstad, T., Vetto, J.T., et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164 (2000), 2160–2169.
123. [123] Montler, R., Bell, R.B., Thalhofer, C., Leidner, R., Feng, Z., Fox, B.A., et al. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin Transl Immunol, 5, 2016, e70, 10.1038/cti.2016.16.
124. [124] Bell, R.B., Leidner, R.S., Crittenden, M.R., Curti, B.D., Feng, Z., Montler, R., et al. OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment. Oral Oncol 52 (2016), 1–10, 10.1016/j.oraloncology.2015.11.009.
125. [125] Piconese, S., Valzasina, B., Colombo, M.P., OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205 (2008), 825–839, 10.1084/jem.20071341.
126. [126] Hirschhorn-Cymerman, D., Rizzuto, G.A., Merghoub, T., Cohen, A.D., Avogadri, F., Lesokhin, A.M., et al. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 206 (2009), 1103–1116, 10.1084/jem.20082205.
127. [127] Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4+ regulatory T cells. J Exp Med 202 (2005), 885–891, 10.1084/jem.20050940.
128. [128] Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., Sakaguchi, S., Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3 (2002), 135–142, 10.1038/ni759.
129. [129] Schaer, D.A., Budhu, S., Liu, C., Bryson, C., Malandro, N., Cohen, A., et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 1 (2013), 320–331, 10.1158/2326-6066.CIR-13-0086.
130. [130] Mitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 16 (2010), 2781–2791, 10.1158/1078-0432.CCR-09-3243.